CD274 and head and neck squamous cell carcinoma: The introduction of immunotherapy targeting the programmed death-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis has represented a turning point in the therapeutic management of HNSCC [4,5,6,7].